Mark J. Poznansky
|Dr. Mark J. Poznansky|
Dr. Mark J. Poznansky is the President and CEO of the Ontario Genomics Institute (OGI).
April 25, 1946 |
|Alma mater||McGill University|
|Occupation||Scientist and Consultant|
|Website||G2G Consulting Website|
Mark J. Poznansky, O.Ont, C.M. (born April 5, 1946) is a research scientist and science administrator. He is the President and CEO of the Ontario Genomics Institute (OGI) and was previously Chair of the Board of OGI, and the founder of G2G Consulting Inc. He is a member of the Order of Canada, a member of the Order of Ontario and the former CEO, President and former Scientific Director of Robarts Research Institute.
Education and early career history
Born in Montreal, Poznansky was educated at McGill University, receiving his PhD in Physiology in 1970. Poznansky completed his postdoctoral training in Biophysics at Harvard Medical School in 1972, where he held the position of Lecturer in Biophysics until 1976. He also served as Charge de Recherche at the Collège de France in Paris from 1973 to 1974.
Poznansky returned to Canada in 1976, taking a position as Associate Professor of Physiology at the University of Alberta in Edmonton. Over the next 18 years, he rose to the rank of Professor and his laboratory developed an international reputation both the areas of cholesterol  and membrane biophysics  as well as enzyme replacement therapy  and the development of novel approaches to drug delivery. In 1984, Poznansky moved on to become the Associate Dean of Medicine at the University of Alberta in Edmonton, a position he held for 9 years.
Robarts Research Institute and the London years
In 1993, Poznansky arrived in London, Ontario, as President and Scientific Director of Robarts Research Institute. He presided over a period of growth, not only in funding and employment but in technology transfer as well. Under his helm from 1993 until 2007, Robarts Research Institute increased its staff from just over 100 to over 600. Annual research funding increased from $10 million per year to over $40 million annually and the Institute spun out 7 different companies including one that was sold to GE Healthcare.
While at Robarts, Poznansky served as President and CEO of London-based Viron Therapeutics Inc. The company was able to bring a candidate drug to the start of Phase II and raised $20 million to support future research efforts.
He was among a group that founded the London Biotechnology Incubator Inc., Ontario’s first Life Sciences incubator. They was able to gain financial support to build a 50,000 sq. ft. facility in London.
The rapid physical and staffing growth of the Institute led to major financial issues in 2007, necessitating the take-over of the Robarts by the University of Western Ontario. Dr. Poznansky stepped down as Scientific Director at that time.
In 2008, Poznansky founded G2G Consulting Inc., offering a wide range of services - such as program reviews, mediation, strategic planning, change management, leadership training and mentoring and management restructuring - to government, hospitals, universities and institutions and the private sector..
Poznansky developed a process to help the Spanish government support the Life Sciences industry. He worked with the Canada Foundation for Innovation  to promote harmony among its committee members and to ensure they worked together to apportion available grant monies objectively.
He helped form a research partnership made up of Robarts Research Institute, Merck & Co, Merck Frosst Canada and GE Healthcare  that was able to receive funding of $20 million over four years, resulting in many key research findings and publications on the subject of lung disease. Poznansky helped change the way the University of Alberta, Edmonton conducted research and helped facilitate the amalgamation of the research administration that occurred when Ottawa Civic and Ottawa General Hospitals merged to create The Ottawa Hospital. He also aided the Thunder Bay Regional Institute in attracting not only some of the "most respected health research minds in Canada"  but those from around the globe.
Poznansky has completed the Negotiation and Advanced Negotiation Workshops at the Harvard Negotiation Institute, Harvard Law School.
Ontario Genomics Institute
Poznansky was appointed as President and CEO of the Ontario Genomics Institute (OGI) on December 1, 2010.
Chairs and board memberships
Poznansky is a founding member and past Chair of the Council for Health Research in Canada, a research advocacy group in Ottawa. He also chaired the Scientific Advisory Board of the Canadian Medical Discoveries Fund  and the board of MDS Capital Corp.
He has sat on the boards of organizations such as Diabetogen, BioMark Inc. and TechAlliance, London. Poznansky has also been a member of numerous science-related committees including the Science Advisory Committee of the Heart and Stroke Foundation of Canada and the Medical Research Council of Canada Grants Panel.
Poznansky lectures widely – both nationally and internationally – on subjects related to the biopharmaceutical industry and research and administration and funding, including technology transfer. He also lectures on Jewish medical ethics as it pertains to human and animal experimentation.
Poznansky led the development of the book Using Our Heads, "a celebration of innovation that was supported by the Ontario Innovation Trust (OIT)." 
- Ontario Genomic Institute Board Member page that presents Dr. Mark Poznansky's biography, including a discussion of his education at McGill and postdoctorate training at Harvard.
- Press release on Dr. Mark Poznansky by Thunder Bay Regional Research Institute that presents biographical information including a discussion of his stints at University of Alberta and Harvard.
- Transbilayer movement of cholesterol in dipalmitoyllecithin−cholesterol vesicles.
- Regulation of human red cell volume by linked cation fluxes published in Journal of Membrane Biology, Volume 10, Number 1/December, 1972, Page 259-266
- Enzyme-Albumin Polymers: New Approaches to the Use of Enzymes in Medicine published in Artificial Cells, Blood Substitutes, and Biotechnology, Volume 15, Issue 4 January 1987, Pages 751 - 774
- A modified tetramethylbenzidine method for measuring lipid hydroperoxides.
- Bioportfolio on Robarts Research Institute.
- Article on discovery by Viron Therapeutics.
- Robarts president awarded Queens Golden Jubi.
- University of Western Ontario press release
- Link provided on web page to download list of participants where Dr. Mark J. Poznansky is listed.
- Canada's most powerful MRI device installed in London.
- Home page from TBRI
- Regional Bioscience Spotlight: Thunder Bay.
- Board listing of Let's Talk Science.
- Article on Dr. Mark Poznansky joining the Thunder Bay Regional Research Institute.
- Address to House of Commons Committee.
- McGill announcement.
- Dr. Mark Poznansky Executive Profile at BusinessWeek.
- Jewish ethics viewed as helpful in medicine by Mara Koven, published in The Canadian Jewish News February 3, 1994, Page 20
- Article on Order of Canada appointments being announced.
- Article on Dr. Mark J. Poznansky being appointed a member of the Order of Ontario.
- The people behind Using Our Heads.